| Company Name: | GenVec, Incorporated | | Ticker Symbol: | GNVC | | | WWW Address: | www.genvec.com | | CEO: | Dr. Paul H. Fischer, Ph.D. | | No. of Employees: | 98 | | Common Issue Type: | CS | | Business Description: | A clinical stage biopharmaceutical company, engaged in the development of novel, gene-based therapeutic drugs and vaccines.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.03 |  0.0 | 0.98 | 1.06 | 0 | 1.16 | 0.97 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 109.5 | 106.3 | 2.18 | -0.31 | 0.00 | 0.0 | 0.0 | 1.17 - 0.30 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.03 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 109.5 | mil |
| Latest Shares Outstanding | 106.3 | mil |
| Earnings pS (EPS) | -0.31 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 154,296 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 93.5 | mil |
| Float as % of Shares Outstanding | 95.1 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 48.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 198.10 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | -123.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -176.3 | % |
| Current Ratio | 3.2 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.10 | $ |
| Cash pS | 0.12 | $ |
| Book-Value pS | 0.11 | $ |
| Tangible Book-Value pS | 0.11 | $ |
| Cash Flow pS | -0.18 | $ |
| Free Cash Flow pS | -0.18 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 9.44 | |
| Price/Tangible Book Ratio | 9.44 | |
| Price/Cash Flow | -5.6 | |
| Price/Free Cash Flow | -5.8 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 17.1 | 115 | 14,148 | 99,235 |
| 4 Weeks | 1.16 | 0.74 | 0.75 | 37.3 | 129 | 15,663 | 266,267 |
| 13 Weeks | 1.16 | 0.71 | 0.76 | 36.3 | 127 | 19,429 | 1,185,184 |
| 26 Weeks | 1.17 | 0.62 | 0.64 | 62.2 | 135 | 18,398 | 2,299,757 |
| 52 Weeks | 1.17 | 0.30 | 0.45 | 128.9 | 185 | 11,005 | 2,740,223 |
| YTD | 1.17 | 0.33 | - | 139.5 | 196 | 11,688 | 2,653,281 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.91 | 0.89 | 0.84 | 0.79 | 0.70 | 2.18 | 2.16 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -1.14 | 0.6 | -10.22 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -5.61 | NA | 6.96 |
| R&D | 3.70 | NA | 0.17 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -11.0 | -30.4 | 7.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.09 | 0.04 | -0.06 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 51.51 |
| Current Ratio | 2.2 |
| Quick Ratio (Acid Test) | 2.1 |
| Liquidity Ratio (Cash) | 1.83 |
| Receivables Turnover | 7.9 |
| Average Collection Period | 46 |
| Working Capital/Equity | 89.6 |
| Working Capital pS | 0.13 |
| Cash-Flow pS | -0.28 |
| Free Cash-Flow pS | -0.27 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.75 |
| Financial Leverage Ratio (Assets/Equity) | 1.7 |
| Debt Ratio | 42.5 |
| Total Debt/Equity (Gearing Ratio) | 0.06 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1.5 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.92 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.65 |
| Tobin's Q Ratio | 4.81 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.96 |
| Enterprise Value (EV)/Free Cash Flow | -4.46 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 9.44 |
| Price/Book Ratio - LTM | 9.44 |
| Price/Cash Flow Ratio | -5.6 |
| Price/Free Cash Flow Ratio - LTM | -5.8 |
| Price/Sales Ratio | 7.92 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.11 |
| Tangible Book Value pS - LTM | 0.11 |
| Book Value pS - LTM | 0.11 |
| Capital Invested pS | 0.12 |
| Cash pS - LTM | 0.12 |
| Cash Flow pS - LTM | -0.18 |
| Free Cash Flow pS - LTM | -0.18 |
| Earnings pS (EPS) | -0.31 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -159.26 |
| Free Cash Flow Margin 5YEAR AVG | -107.75 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 1.16 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.16 |
| Return on Capital Invested (ROCI) | -199.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -73.5 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | -114.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | -54.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 50 |
| Revenue per Employee | 154,296 |
| Net Income per Employee | -265,949 |
| Average Collection Period | 50 |
| Receivables Turnover | 7.9 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 12.92 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.29 |
| Fixed Assets Turnover | 9.71 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 1.06 |
| Revenue per $ Plant | 9.76 |
| Revenue per $ Common Equity | 1.16 |
| Revenue per $ Capital Invested | 1.16 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 52.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 49.9 |
| Research & Devlopment (R&D) as % of Revenue | 223.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 223.7 |
|
|  
| | |  |  | |
| |